Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥24.65B
Enterprise Value¥21.31B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthJapan Tissue Engineering's near-zero debt and equity-financed capital structure provide durable financial flexibility. That low leverage supports investment in costly cell-manufacturing capacity, R&D and regulatory programs without high interest burden, reducing refinancing risk during multi-year product rollouts.
High Gross MarginsSustained high gross margins indicate favorable unit economics for tissue-engineered products and services. Strong product-level profitability creates room to absorb fixed manufacturing and quality-control costs as volume scales, improving the path to durable operating leverage once sales growth stabilizes.
Revenue Growth MomentumMaterial multi-year revenue gains reflect accelerating commercial adoption of products and services. Durable top-line momentum supports scaling manufacturing and contract-service lines, which can amplify margins over time if management controls operating expenses and converts demand into repeatable sales.
Bears Say
Inconsistent ProfitabilityVolatile profitability demonstrates the company struggles to translate revenue into stable earnings. These swings suggest operating costs, commercialization expenses or scaling inefficiencies are not yet predictable, increasing execution risk for multi-quarter planning and reducing confidence in margin sustainability.
Weak Cash GenerationRepeated negative operating and free cash flow mean the business is not yet self-funding its growth and capital needs. Persistent cash burn creates reliance on external financing or partnerships, raising dilution and timing risk and constraining the company's ability to invest opportunistically or weather downturns.
Regulatory & Reimbursement DependencyThe firm's economics depend on successful regulatory approvals, robust quality systems and securing reimbursement—structural industry hurdles that can slow adoption and revenue recognition. These enduring dependencies increase timeline uncertainty and can materially affect margins and cash flows over many months.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥24.65B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is May 01, 2026 which is in 11 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jan 30, 2026. The company reported -¥4.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.56.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.